Search Results - "Louis, Edouard J"

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohnʼs disease: a subanalysis of the ACCENT I study by Louis, Edouard J, Watier, Hervé E, Schreiber, Stefan, Hampe, Jochen, Taillard, François, Olson, Allan, Thorne, Nicole, Zhang, Hongyan, Colombel, Jean-Frédéric

“…Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohnʼs disease. We…”
Get full text

Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies by Louis, Edouard J., Reinisch, Walter, Schwartz, David A., Löfberg, Robert, Robinson, Anne M., Berg, Sofie, Wang, Anthony W., Maa, Jen-fue, Huang, Bidan, Pappalardo, Brandee

“…Introduction Extraintestinal manifestations (EIMs) in patients with Crohn’s disease (CD) are common and associated with additional morbidity. This study aimed…”
Get full text

Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy by De Vos, Martine, Louis, Edouard J, Jahnsen, Jørgen, Vandervoort, Jo G P, Noman, Maja, Dewit, Olivier, Dʼhaens, Geert R, Franchimont, Denis, Baert, Filip J, Torp, Roald A, Henriksen, Magne, Potvin, Philippe M R, Van Hootegem, Philippe P, Hindryckx, Pieter M, Moreels, Tom G, Collard, Arnaud, Karlsen, Lars Normann, Kittang, Eirik, Lambrecht, Guy, Grimstad, Tore, Koch, Jonas, Lygren, Idar, Coche, Jean-Claude R J, Mana, Fazia, Van Gossum, André, Belaiche, Jacques, Cool, Mike R, Fontaine, Fernand, Maisin, Jean-Marc G, Muls, Vinciane, Neuville, Bart, Staessen, Dirk A J, Van Assche, Gert A, de Lange, Thomas, Solberg, Inger Camilla, Vander Cruyssen, Bert J K, Vermeire, Severine A R A

“…This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab…”
Get full text

Sustained Resolution of Extraintestinal Manifestations in Patients with Crohnʼs Disease Receiving Adalimumab: 670 by Schwartz, David, Louis, Edouard J., Löfberg, Robert, Reinisch, Walter, Maa, Jen-fue, Berg, Sofie, Huang, Bidan, Wang, Anthony W., Robinson, Anne M., Pappalardo, Brandee

Get full text

Are we giving biologics too much time？ When should we stop treatment by Louis, Edouard, Belaiche, J, Reenaers, C

“…The optimal duration of biological treatment, particularly anti-TNF, in inflammatory bowel disease （IBD） is a very important question both for patients and…”
Get full text

Location and behavior of Crohn's disease according to Vienna classification evolution over the course of the disease by Louis, Edouard J., Collard, Amaud, Oger, Anne-Francoise, Groote, Elodie De, Belaiche, Jacques

Get full text

Are systemic inflammatory markers useful in the prediction of response to infliximab in Crohn's disease? by Louis, Edouard J., Vermeire, Severine, Rutgeerts, Paul, De Vos, Martine, Van Gossum, Andre, Pescatore, Paul, Flasse, Rene, Pelckmans, Paul, Reynaert, H, D'Haens, Geert, Malaise, Michel, Belaiche, Jacques

Get full text